MedTrace Logo

Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

NCT00174967 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2011-07-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout.

Conditions

Interventions

DRUG

Placebo

Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.

DRUG

Febuxostat

Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.

DRUG

Febuxostat

Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.

DRUG

Febuxostat

Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2001-07-31
Completion
2001-07-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00174967 on ClinicalTrials.gov